BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25948101)

  • 1. Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults.
    Koblan KS; Hopkins SC; Sarma K; Jin F; Goldman R; Kollins SH; Loebel A
    Neuropsychopharmacology; 2015 Nov; 40(12):2745-52. PubMed ID: 25948101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial.
    Findling RL; Adler LA; Spencer TJ; Goldman R; Hopkins SC; Koblan KS; Kent J; Hsu J; Loebel A
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):80-89. PubMed ID: 30694697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial.
    Adler LA; Goldman R; Hopkins SC; Koblan KS; Kent J; Hsu J; Loebel A
    Int Clin Psychopharmacol; 2021 May; 36(3):117-125. PubMed ID: 33724251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
    Wigal TL; Newcorn JH; Handal N; Wigal SB; Mulligan I; Schmith V; Konofal E
    CNS Drugs; 2018 Mar; 32(3):289-301. PubMed ID: 29557078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.
    Brams M; Childress AC; Greenbaum M; Yu M; Yan B; Jaffee M; Robertson B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):19-28. PubMed ID: 28816509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study.
    Spencer TJ; Adler LA; Weisler RH; Youcha SH
    J Clin Psychiatry; 2008 Sep; 69(9):1437-48. PubMed ID: 19012813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study.
    Wigal SB; Hopkins SC; Koblan KS; Childress A; Kent JM; Tsai J; Hsu J; Loebel A; Goldman R
    J Atten Disord; 2020 Jan; 24(2):192-204. PubMed ID: 31375051
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
    Iwanami A; Saito K; Fujiwara M; Okutsu D; Ichikawa H
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32297719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
    Swanson JM; Greenhill LL; Lopez FA; Sedillo A; Earl CQ; Jiang JG; Biederman J
    J Clin Psychiatry; 2006 Jan; 67(1):137-47. PubMed ID: 16426100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate.
    Weisler RH; Babcock T; Adeyi B; Brams M
    Postgrad Med; 2014 Sep; 126(5):31-41. PubMed ID: 25295648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Placebo-Controlled, Flexible-Dose Clinical Trial.
    McElroy SL; Hudson JI; Grilo CM; Guerdjikova AI; Deng L; Koblan KS; Goldman R; Navia B; Hopkins S; Loebel A
    J Clin Psychiatry; 2020 Sep; 81(5):. PubMed ID: 32926604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.